NCT06698003 2026-03-05
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06235281 2026-02-27
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Suspended
NCT04848064 2026-02-10
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT05956041 2026-01-07
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT04930653 2025-10-14
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT05414500 2025-08-08
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT04256018 2025-07-02
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Phase 2 Recruiting
NCT04676087 2024-08-13
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Emory University
Phase 1/2 Terminated
NCT02281409 2021-04-23
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed
NCT01929486 2016-02-17
Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Aichi Medical University
Phase 1 Unknown